BACKGROUND: Screening and early diagnosis tools are lacking for pancreatic adenocarcinoma; most patients are diagnosed with metastatic disease. Autoantibodies to tumor-associated antigens (TAAs) can be present months to years before diagnosis and hold promise as biomarkers for early detection. METHODS: TAAs to pancreatic cancer autoantibodies CTDSP1 (carboxy-terminal domain, RNA polymerase II, polypeptide A, small phosphatase 1), MAPK9 (mitogen-activated protein kinase 9), and NR2E3 (nuclear receptor subfamily 2, group E, member 3), which were identified as potentially promising biomarkers in exploratory studies, were evaluated in serum from participants (300 cases, 300 controls) in a population-based case-control pancreatic cancer study in the San Francisco Bay Area. Patients were identified through cancer registry rapid case ascertainment, newly diagnosed from 1995 to 1999 and followed up through 2008. Autoantibody levels were analyzed as continuous and grouped (quartiles) variables. Multivariable unconditional logistic regression was used to compute odds ratios (ORs) as estimates of autoantibody levels associated with disease status. Kaplan-Meier product limit estimates and multivariable Cox proportional hazards regression were used to assess autoantibody levels associated with case survival duration. RESULTS: Cases had higher levels of CTDSP1 (P = .004), MAPK9 (P = .0002), and NR2E3 (P ≤ .0001) autoantibodies than controls (fourth vs first quartile: CTDSP1 OR = 1.7, MAPK9 OR = 2.5, NR2E3 OR = 4.0). High body mass index and tobacco use were associated with levels in controls but were not statistical confounders. High CTDSP1 levels were somewhat associated with better survival (hazard ratio = 0.77, P = .07). CONCLUSIONS: Combined with previous results, this study contributes evidence that cancer-related host immune-response factors may be useful diagnostic screening tools and prognostic indicators for pancreatic cancer. Further studies are needed to critically assess the value of autoantibody panels to TAAs in diagnostic screening, prognosis, and immunotherapy of pancreatic and other cancers.
BACKGROUND: Screening and early diagnosis tools are lacking for pancreatic adenocarcinoma; most patients are diagnosed with metastatic disease. Autoantibodies to tumor-associated antigens (TAAs) can be present months to years before diagnosis and hold promise as biomarkers for early detection. METHODS: TAAs to pancreatic cancer autoantibodies CTDSP1 (carboxy-terminal domain, RNA polymerase II, polypeptide A, small phosphatase 1), MAPK9 (mitogen-activated protein kinase 9), and NR2E3 (nuclear receptor subfamily 2, group E, member 3), which were identified as potentially promising biomarkers in exploratory studies, were evaluated in serum from participants (300 cases, 300 controls) in a population-based case-control pancreatic cancer study in the San Francisco Bay Area. Patients were identified through cancer registry rapid case ascertainment, newly diagnosed from 1995 to 1999 and followed up through 2008. Autoantibody levels were analyzed as continuous and grouped (quartiles) variables. Multivariable unconditional logistic regression was used to compute odds ratios (ORs) as estimates of autoantibody levels associated with disease status. Kaplan-Meier product limit estimates and multivariable Cox proportional hazards regression were used to assess autoantibody levels associated with case survival duration. RESULTS: Cases had higher levels of CTDSP1 (P = .004), MAPK9 (P = .0002), and NR2E3 (P ≤ .0001) autoantibodies than controls (fourth vs first quartile: CTDSP1 OR = 1.7, MAPK9 OR = 2.5, NR2E3 OR = 4.0). High body mass index and tobacco use were associated with levels in controls but were not statistical confounders. High CTDSP1 levels were somewhat associated with better survival (hazard ratio = 0.77, P = .07). CONCLUSIONS: Combined with previous results, this study contributes evidence that cancer-related host immune-response factors may be useful diagnostic screening tools and prognostic indicators for pancreatic cancer. Further studies are needed to critically assess the value of autoantibody panels to TAAs in diagnostic screening, prognosis, and immunotherapy of pancreatic and other cancers.
Authors: Andreas Wadle; Boris Kubuschok; Jochen Imig; Beate Wuellner; Christine Wittig; Carsten Zwick; Axel Mischo; Kristin Waetzig; Bernd F M Romeike; Werner Lindemann; Martin Schilling; Michael Pfreundschuh; Christoph Renner Journal: Int J Cancer Date: 2006-07-01 Impact factor: 7.396
Authors: Xiaoju Wang; Jianjun Yu; Arun Sreekumar; Sooryanarayana Varambally; Ronglai Shen; Donald Giacherio; Rohit Mehra; James E Montie; Kenneth J Pienta; Martin G Sanda; Philip W Kantoff; Mark A Rubin; John T Wei; Debashis Ghosh; Arul M Chinnaiyan Journal: N Engl J Med Date: 2005-09-22 Impact factor: 91.245
Authors: Raluca A Budiu; Gina Mantia-Smaldone; Esther Elishaev; Tianjiao Chu; Julia Thaller; Kathryn McCabe; Diana Lenzner; Robert P Edwards; Anda M Vlad Journal: Cancer Immunol Immunother Date: 2011-04-02 Impact factor: 6.968
Authors: Patrick Maisonneuve; Albert B Lowenfels; H Bas Bueno-de-Mesquita; Parviz Ghadirian; Peter A Baghurst; Witold A Zatonski; Anthony B Miller; Eric J Duell; Paolo Boffetta; Peter Boyle Journal: Ann Epidemiol Date: 2010-02 Impact factor: 3.797
Authors: Sara H Olson; Irene Orlow; Jennifer Simon; Diana Tommasi; Pampa Roy; Sharon Bayuga; Emmy Ludwig; Ann G Zauber; Robert C Kurtz Journal: Cancer Detect Prev Date: 2007-11-26
Authors: P Boyle; C J Chapman; S Holdenrieder; A Murray; C Robertson; W C Wood; P Maddison; G Healey; G H Fairley; A C Barnes; J F R Robertson Journal: Ann Oncol Date: 2010-07-30 Impact factor: 32.976
Authors: Phillip Stafford; Zbigniew Cichacz; Neal W Woodbury; Stephen Albert Johnston Journal: Proc Natl Acad Sci U S A Date: 2014-07-14 Impact factor: 11.205
Authors: M Oliverius; D Flasarova; B Mohelnikova-Duchonova; M Ehrlichova; V Hlavac; M Kocik; O Strouhal; P Dvorak; I Ojima; P Soucek Journal: Mutagenesis Date: 2019-12-19 Impact factor: 3.000
Authors: Christine G Parks; Frederick W Miller; Minoru Satoh; Edward K L Chan; Zhanna Andrushchenko; Linda S Birnbaum; Todd A Jusko; Grace E Kissling; Mehul D Patel; Kathryn M Rose; Clarice Weinberg; Darryl C Zeldin; Dale P Sandler Journal: Cancer Epidemiol Biomarkers Prev Date: 2014-08-01 Impact factor: 4.254
Authors: Julie-Ann O'Reilly; Jenny Fitzgerald; Seán Fitzgerald; Dermot Kenny; Elaine W Kay; Richard O'Kennedy; Gregor S Kijanka Journal: PLoS One Date: 2015-04-13 Impact factor: 3.240